Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipid-lowering drugs and risk of rapid renal function decline: a mendelian randomization study.

BMC medical genomics - 8 Oct 2024

Zhao Zhicheng, Wan Yu, Fu Han, Ying Shuo, Zhang Peng, Meng Haoyu, Song Yu, Fu Naikuan

Abstract excerpt

BACKGROUND: Chronic kidney disease (CKD) patients face the risk of rapid kidney function decline leading to adverse outcomes like dialysis and mortality. Lipid metabolism might contribute to acute kidney function decline in CKD patients. Here, we utilized the Mendelian Randomization approach to investigate potential causal relationships between drug target-mediated lipid phenotypes and rapid renal function...

Topics

Join the communities discussing this publication.

Cholesterol, LDL
Genome-Wide Association Study
Hypolipidemic Agents
Kidney
Mendelian Randomization Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Proprotein Convertase 9

Quantitative Trait Loci

Renal Insufficiency, Chronic

Source

Open in PubMed Open full text

Identifiers

PMID: 39379957
DOI: 10.1186/s12920-024-02020-4
PMCID: PMC11463126

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipid-lowering drugs and risk of rapid renal function decline: a mendelian randomization study.PMID 39379957Read ↗

Lipid-Lowering Drugs and Risk of Rapid Renal Function Decline: A Mendelian Randomization StudySemantic proximity Read ↗

Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease.Semantic proximity Read ↗

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization studySemantic proximity Read ↗

Cardiometabolic drugs and kidney function – a drug target Mendelian randomisation studySemantic proximity Read ↗

Comprehensive Druggable Genome-Wide Mendelian Randomization Reveals Therapeutic Targets for Kidney DiseasesSemantic proximity Read ↗

Deciphering the Effect of High-Density Lipoprotein Cholesterol on Renal Function: a Mendelian Randomization StudySemantic proximity Read ↗

Kidney function decline and kidney stone risk: cohort and Mendelian randomization analyses.Semantic proximity Read ↗

An interracial Mendelian analysis revealed a link between lipid-lowering drugs and renal failure.Semantic proximity Read ↗

The causal effects of serum lipids and apolipoproteins on kidney function: multivariable and bidirectional Mendelian-randomization analysesSemantic proximity Read ↗

Mendelian Randomization Analysis as a Tool to Gain Insights into Causes of Diseases: A Primer.Semantic proximity Read ↗

Effects of genetically proxied statins on diabetic nephropathy and retinopathy: a Mendelian randomization study.Semantic proximity Read ↗

Higher genetically predicted low-density lipoprotein levels increase the renal cancer risk independent of triglycerides and high-density lipoprotein levels: A Mendelian randomization study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.